LXRX - レキシコン・ファ―マシュ―ティカルズ (Lexicon Pharmaceuticals Inc.)

LXRXのニュース

   Late-Stage Diabetes Study Sets the Stage for Lexicon Pharma  2020/07/21 14:56:35 24/7 Wall street
   HotStocks USA: +39% bei LEXICON PHARMA, +29% bei INFLARX  2020/07/21 13:00:00 GodmodeTrader
Anbei erhalten Sie eine Übersicht über die Werte, die vorbörslich an der Nasdaq am meisten Aufmerksamkeit bei den Anlegern erregen.
   Lexicon Pharmaceuticals Announces Poster Presentations at the Virtual Cholangiocarcinoma Foundation Annual Conference  2020/07/20 11:00:00 GlobeNewswire
THE WOODLANDS, Texas, July 20, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that four posters highlighting…
   Lexicon Pharmaceuticals Presents Clinical Data at 80th American Diabetes Association Scientific Sessions | MarketScreener  2020/06/13 15:02:02 MarketScreener
THE WOODLANDS, Texas, June 13, 2020 -- Lexicon Pharmaceuticals, Inc. , today presented six posters for ZynquistaTM at the virtual 80th American Diabetes Association Scientific… | June 13, 2020
   Lexicon Pharmaceuticals (NASDAQ: LXRX) Q1 2020 Earnings Call Transcript  2020/04/27 15:04:43 news.alphastreet.com
Lexicon Pharmaceuticals (LXRX) Q1 2020 earnings call dated Apr. 27, 2020 Corporate Participants: Kimberly Lee — Head of Investor Relations and Corporate Strategy Lonnel Coats — President and Chief Executive Officer and Director Pablo Lapuerta — Executive Vice President and Chief Medical Officer Jeffrey L. Wade — Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer Presentation: Operator Ladies and gentlemen, […]
   Lexicon Pharmaceuticals (NASDAQ: LXRX) Q1 2020 Earnings Call Transcript  2020/04/27 15:04:43 news.alphastreet.com
Lexicon Pharmaceuticals (LXRX) Q1 2020 earnings call dated Apr. 27, 2020 Corporate Participants: Kimberly Lee — Head of Investor Relations and Corporate Strategy Lonnel Coats — President and Chief Executive Officer and Director Pablo Lapuerta — Executive Vice President and Chief Medical Officer Jeffrey L. Wade — Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer Presentation: Operator Ladies and gentlemen, […]
   Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for  2020/03/04 17:30:30 Zacks Investment Research
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Lexicon Pharmaceuticals : Helena rancher participates in national Young Farmer & Rancher competition  2020/01/20 21:09:06 MarketScreener
Montana Farm Bureau Discussion Meet winner Rocky Forseth competed in two rounds of the national YF&R Discussion Meet during the American Farm Bureau Convention January 18 in Austin….
   Lexicon Pharmaceuticals Completes a Safety Review in TELE-ABC  2019/12/03 17:06:36 Investing News Network
The company has announced it has completed the safety of an initial run-in cohort of its TELE-ABC Phase 2 clinical study. The post Lexicon Pharmaceuticals Completes a Safety Review in TELE-ABC appeared first on Investing News Network .
   Why Lexicon Pharma Shares Are Moving Lower  2019/12/02 16:09:45 Benzinga
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) shares were retreating sharply Monday morning on an adverse development with its Type 1 diabetes drug candidate sotagliflozin. Lexicon was co-developing the pipeline asset with Sanofi SA (NASDAQ: SNY ) but has terminated the alliance effective Sept. 9. FDA Firm On Rejection Decision The actively traded, small-cap biotech Lexicon said it has been notified by the Office of New Drugs of the FDA that the agency is standing by its prior position and denying the company's appeal of the complete response letter related to its NDA for its Type 1 diabetes drug sotagliflozin. Sotagliflozin, going by the trade name Zynquista, is an oral dual inhibitor of two proteins responsible for … Full story available on Benzinga.com
   Lexicon Pharmaceuticals (NASDAQ: LXRX) Q1 2020 Earnings Call Transcript  2020/04/27 15:04:43 news.alphastreet.com
Lexicon Pharmaceuticals (LXRX) Q1 2020 earnings call dated Apr. 27, 2020 Corporate Participants: Kimberly Lee — Head of Investor Relations and Corporate Strategy Lonnel Coats — President and Chief Executive Officer and Director Pablo Lapuerta — Executive Vice President and Chief Medical Officer Jeffrey L. Wade — Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer Presentation: Operator Ladies and gentlemen, […]
   Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for  2020/03/04 17:30:30 Zacks Investment Research
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Lexicon Pharmaceuticals : Helena rancher participates in national Young Farmer & Rancher competition  2020/01/20 21:09:06 MarketScreener
Montana Farm Bureau Discussion Meet winner Rocky Forseth competed in two rounds of the national YF&R Discussion Meet during the American Farm Bureau Convention January 18 in Austin….
   Lexicon Pharmaceuticals Completes a Safety Review in TELE-ABC  2019/12/03 17:06:36 Investing News Network
The company has announced it has completed the safety of an initial run-in cohort of its TELE-ABC Phase 2 clinical study. The post Lexicon Pharmaceuticals Completes a Safety Review in TELE-ABC appeared first on Investing News Network .
   Why Lexicon Pharma Shares Are Moving Lower  2019/12/02 16:09:45 Benzinga
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) shares were retreating sharply Monday morning on an adverse development with its Type 1 diabetes drug candidate sotagliflozin. Lexicon was co-developing the pipeline asset with Sanofi SA (NASDAQ: SNY ) but has terminated the alliance effective Sept. 9. FDA Firm On Rejection Decision The actively traded, small-cap biotech Lexicon said it has been notified by the Office of New Drugs of the FDA that the agency is standing by its prior position and denying the company's appeal of the complete response letter related to its NDA for its Type 1 diabetes drug sotagliflozin. Sotagliflozin, going by the trade name Zynquista, is an oral dual inhibitor of two proteins responsible for … Full story available on Benzinga.com

calendar